Maintenance Treatment of Chidamide in Stage IV or Relapsed/Refractory Extranodal NK/T-cell Lymphoma

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type Clinical Trial

Official title:
Maintenance Treatment of Chidamide in Chemotherapy-responded Stage IV or Relapsed/Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type

Status Recruiting

Clinical Trial Summary

Extranodal natural killer/T-cell lymphoma, nasal type (NKTCL) is a highly aggressive peripheral T-cell lymphoma (PTCL). Patients with newly diagnosed stage IV and relapsed/refractory have poor prognosis. 5-year progression-free survival was reported only 55%. Chidamide is a selective histone deacetylase inhibitor which was approved by FDA in treating relapsed or refractory PTCL. In phase I and II studies of chidamide, patients with relapsed or refractory NKTCL achieved a higher overall remission. Patients who obtained complete or partial remission had much favourable duration of remission. Thus, the invesgator design this study to evaluate the role of maintenance treatment of chidamide for induction chemotherapy-responded newly-diagnosed advanced and relapsed/refractory NKTCL patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Lymphoma
Lymphoma, Extranodal NK-T-Cell
Lymphoma, T-Cell
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

Clinical Trial Details

NCT number	NCT03630731
Study type	Interventional
Source	Chinese Academy of Medical Sciences
Contact	Mei Dong
Phone	13811929322
Email	dongmei030224@163.com
Status	Recruiting
Phase	Phase 2
Start date	August 2018
Completion date	March 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05058755` - Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma	N/A
Recruiting	`NCT06314334` - Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma	Phase 2
Completed	`NCT03618238` - Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma	Phase 2
Recruiting	`NCT04004572` - Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma	Phase 2
Recruiting	`NCT03623087` - SIMPLE Chemotherapy for NK Lymphoma/Leukaemia	Phase 3
Recruiting	`NCT03107962` - Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma	Phase 2
Completed	`NCT03936452` - Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma	Phase 2
Recruiting	`NCT04366128` - Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL	N/A
Recruiting	`NCT06376721` - Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma	Phase 1/Phase 2